Devangi Desai, MD
Internal Medicine · Sparks, NVNPI 1710155163
Payments from drug & device makers
Across 82 payments — averaging $51.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Abbott$665
- Edwards Lifesciences$377
- AbbVie$202
- GSK$135
- Boehringer Ingelheim$100
- plus $529 from 17 others
What the payments were for
- Speaking & faculty fees$2,00047%
- Food & beverage$2,22053%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $2,213 |
| Abbott | 19 | $665 |
| Edwards Lifesciences | 11 | $377 |
| AbbVie | 10 | $202 |
| GSK | 9 | $135 |
| Boehringer Ingelheim | 2 | $100 |
| Boston Scientific | 2 | $94 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Pfizer | 3 | $53 |
| Medtronic | 1 | $50 |
| Novo Nordisk | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $33 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $26 |
| AstraZeneca | 2 | $24 |
| United Therapeutics Corporation | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Akcea Therapeutics, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Merck | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $13 |
| Cardiovascular Systems Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,220 in reported general payments places this provider in the 85th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $145,876 |
| JardianceEmpagliflozin | 91 | $110,935 |
| TrulicityDulaglutide | 41 | $59,488 |
| EliquisApixaban | 33 | $48,044 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $29,696 |
| MounjaroTirzepatide | 15 | $23,820 |
| SynjardyEmpagliflozin/Metformin Hcl | 15 | $20,978 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $16,140 |
| JanuviaSitagliptin Phosphate | 12 | $15,416 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $11,805 |
| Atorvastatin Calcium | 470 | $7,818 |
| SynthroidLevothyroxine Sodium | 74 | $6,550 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,114 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $5,975 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 28 | $5,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $36 | $145,87696 claims |
| Boehringer IngelheimJardiance, Synjardy | $100 | $131,913106 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $20 | $83,30956 claims |
| PfizerEliquis, Paxlovid | $53 | $49,47344 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $135 | $33,85161 claims |
| MerckJanuvia | $16 | $15,41612 claims |
| AbbVieSynthroid | $202 | $6,55074 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Sparks
- Darin BrimhallLas Vegas$39.7M
- Alton WaltersLas Vegas$8.9M
- Michael JacobsLas Vegas$8.1M
- Nirupa PaulrajLas Vegas$5.8M
- Atoya AdamsLas Vegas$5.4M
- Roger EstevezLas Vegas$3.7M
- Syed PervaizLas Vegas$3.1M
- Marigene Salazar SharmaHenderson$2.5M
- Mavis MatsumotoHenderson$1.8M
- Vrijendra HoonLas Vegas$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.